Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill
Anti-CD 20 therapies have found significant uses in multiple sclerosis (MS). Based singularly on the accumulated evidence with the use of rituximab (RTX; Rituxan, Genentech, and Biogen) in neuroimmunological diseases, ocrelizumab (OCR; Ocrevus, Genentech) was developed as a treatment option for MS a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2017-10-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.1177/1177392817737515 |